BPX-101: Additional Phase I/II data

Additional data from an open-label, dose-escalation, U.S. Phase I/II trial in 12 patients showed that low-, mid- and high-doses of intradermal BPX-101 given every other week in combination with AP1903 for 6 doses produced a partial or complete response in 3 patients. Additionally, 2 patients experienced a PSA decline approaching 50% within the first 12 weeks of treatment. Data were presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium in Orlando. ...